APA (7th ed.) Citation

T, K., S, S., I, R., MS, F., H, A., J, B., . . . A, K. (2023). Comparative Effectiveness of Autologous Hematopoietic Stem Cell Transplant vs Fingolimod, Natalizumab, and Ocrelizumab in Highly Active Relapsing-Remitting Multiple Sclerosis. JAMA neurology, 80(7), 702. https://doi.org/10.1001/jamaneurol.2023.1184

Chicago Style (17th ed.) Citation

T, Kalincik, et al. "Comparative Effectiveness of Autologous Hematopoietic Stem Cell Transplant Vs Fingolimod, Natalizumab, and Ocrelizumab in Highly Active Relapsing-Remitting Multiple Sclerosis." JAMA Neurology 80, no. 7 (2023): 702. https://doi.org/10.1001/jamaneurol.2023.1184.

MLA (9th ed.) Citation

T, Kalincik, et al. "Comparative Effectiveness of Autologous Hematopoietic Stem Cell Transplant Vs Fingolimod, Natalizumab, and Ocrelizumab in Highly Active Relapsing-Remitting Multiple Sclerosis." JAMA Neurology, vol. 80, no. 7, 2023, p. 702, https://doi.org/10.1001/jamaneurol.2023.1184.